14 Vasopressin synthesized in the magnocellular neurons of the paraventricular and supraoptic nuclei is transported via axonal transport to the posterior pituitary where it is secreted into the bloodstream in response to a number of stimuli (Fig I) .
Transgenic Mouse Models of Vasopressin Expression
V asopressin is synthesized primarily in three regions of the hypothalamus: the paraventricular nuclei, supraoptic nuclei, and suprachiasmatic nuclei. 14 Vasopressin synthesized in the magnocellular neurons of the paraventricular and supraoptic nuclei is transported via axonal transport to the posterior pituitary where it is secreted into the bloodstream in response to a number of stimuli (Fig I) . 5 ' 6 Increases in plasma osmolality as small as 2% can stimulate secretion of vasopressin, 5 ' 6 which then acts to promote water reabsorption in the distal tubules and collecting ducts of the kidney. 7 Secretion of vasopressin is also affected by changes in blood volume and blood pressure as sensed by baroreceptors located in the heart, aorta, and carotid sinus. With a marked decrease in blood volume or blood pressure, the baroreceptor mechanism can cause secretion of large quantities of vasopressin from the posterior pituitary. 5 - 8 Other less potent stimuli of magnocellular vasopressin secretion include fever and emesis. 6 High levels of plasma vasopressin cause arteriolar vasoconstriction, although vasopressin may also cause local vasodilation in the arteries of the forearm. 9 Vasopressin is also synthesized in parvocellular neurons of the hypothalamus. Some parvocellular neurons project to the median eminence, where vasopressin is released into the portal circulation of the pituitary gland. Vasopressin acts synergistically with corticotropin-releasing hormone to stimulate release of corticotropin from corticotrophic cells in the anterior pituitary. 10 Vasopressin synthesized in the parvocellular neurons of the supraoptic nuclei is not released into the bloodstream but instead appears to be the source of vasopressin in the cerebrospinal fluid and may have a role in the regulation of circadian rhythms. 1112 Vasopressin has been identified in other regions of the brain, including the temporal lobe of the rat brain. 1314 Although the function of vasopressin in these sites is not clear, it may be involved in processes other than water metabolism, such as the central regulation of blood pressure. 1517 Vasopressin peptide has been found in the human and rat pancreas. 1819 Immunologic techniques have also shown vasopressin peptide in the adrenal, ovary, and testes. 2022 In situ hybridization techniques have demonstrated vasopressin mRNA in the amygdala of the rat brain. processed within the secretory granule during axonal transport from the hypothalamus to the posterior pituitary. 25 Although they are released in equimolar quantities with vasopressin, the roles of the neurophysin and gh/copeptide are not known. In vitro evidence suggests that they may be involved in intracellular transport of vasopressin, 26 but in vivo each also could have a function independent of vasopressin. 27 Molecular cloning and sequencing of the rat 28 and mouse 29 vasopressin genes has allowed the identification of putative cis-acting elements in the upstream promoter region 30 that may have a role in the regulation of vasopressin expression (Fig 2) . Although the function of these putative cis-acting elements can be studied using in vitro methods, the role of each in the in vivo physiological regulation of vasopressin expression is not known.
Regulation of Vasopressin Gene Expression
In rats, the osmotic stimulus of water deprivation causes an increase in hypothalamic vasopressin mRNA. 3 In situ hybridization studies have shown this increase to occur in the magnocellular neurons of the hypothalamus. 4 Northern blot analysis has also demonstrated that, with osmotic stimulation, the length of vasopressin mRNA increases because of an increase in the length of the mRNA polyadenylate [poly(A)] tail. 31 Potential roles for this increase in poly(A) tail length include increasing the translational efficiency 32 and halflife 33 of mRNA. In mice, osmotic stimulation causes an increase in vasopressin mRNA quantity without a change in the length of the mRNA. 34 Therefore, regulation of poly(A) tail length differs among species and may be due to differences in cis-acting elements in the vasopressin genes or cell-or species-specific trans-activating cellular factors.
-
Vasopressin gene regulation has also been studied in vitro using both primary hypothalamic cell cultures and heterologous continuous cell lines. In primary cultures of rat hypothalamic cells, vasopressin mRNA quantity and length increase in response to exposure to forskolin, a stimulator of protein kinase A. 35 Stimulation of the protein kinase C pathway causes an increase in vasopressin mRNA size without a concurrent increase in mRNA quantity. 35 In AtT-20 cells, a mouse pituitary tumor cell line, transfected with the rat vasopressin gene, stimulation with forskolin causes an increase in size and quantity of vasopressin mRNA, but there is no response with stimulation of the protein kinase C pathway. 36 In the same transfected cell lines, glucocorticoids will suppress vasopressin mRNA expression.
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Transgenic Models of Gene Expression
The effect of physiological and pharmacologic stimuli on vasopressin peptide levels has been well studied in whole animal models, whereas the role of second messengers in the regulation of vasopressin gene regulation is best studied with in vitro methods, such as cell culture. Molecular biology techniques have demonstrated the effects of physiological stimuli, such as water deprivation, on expression of vasopressin mRNA in the hypothalamus. However, a further understanding of the importance of various cis-acting elements in the physiological regulation of the vasopressin gene requires a model in which altered constructs of the vasopressin gene can be studied in vivo in a whole animal model. 
FIG 2. Schematic shows structure of vasopressin (VP) gene and preprohormone. The vasopressin gene includes three exons: A (168 bp), B (202 bp), and C (240 bp), separated by two introns: I (1234 bp) and II (177 bp). Putative cis-acting sequences in the 5' promoter region upstream to the transcription start site (arrow) include potential cyclic AMP (CRE) and glucocorticoid (GRE) response elements andAP2 binding sites. Messenger RNA is transcribed from the transcription initiation site (arrow) to the poly (A) tail addition site (a). Exon A encodes vasopressin peptide and the signal peptide of the preprohormone. Vasopressin-related neurophysin is encoded by exon B as well as contiguous regions of exons A and C. Exon C also encodes the vasopressin-related gtycopeptide.
sion may also be useful in determining the functions and importance of the neurophysin and glycopeptide encoded by the vasopressin gene. The technique of pronuclear injection 38 ' 39 can be used to incorporate a foreign gene into the genome of a host animal. When successfully incorporated into the genome, the transgene usually will be passed on to subsequent offspring in a Mendelian manner. To be a useful model of gene expression, the structural gene and all important cis-acting promoter/enhancer elements should be included in the transgenic construct. 40 ' 41 Genes expressed in several different tissues may have ci?-acting sequences important for expression in each tissue. 42 The site of integration of the transgene into the host genome may exert an effect on expression of the transgene. However, if the transgene includes all the important promoter/enhancer sequences of the gene, then the integration site becomes less important in gene expression and its regulation. 43 For studies of normal physiology, the transgene gene should meet two requirements. First, there should be tissue-specific expression of the transgene. Without expression of the transgene in tissues in which the gene is normally expressed, the response to physiological stimuli cannot be studied. However, generalized expression of the transgene throughout the body could alter the physiology of the host animal. Second, there should be normal physiological regulation of the transgene. However, transgenic animals that overexpress a transgene may be useful in studies to determine the role of the gene product.
Previous Transgenic Models Using the Vasopressin Gene
In the first reported study of mice transgenic for a vasopressin construct, Murphy et al 44 used a fusion gene with 1.25 kb of the rat vasopressin promoter driving the coding sequence for the SV40 T antigen. These animals developed tumors of the anterior pituitary and pancreatic islet beta cells, but the hypothalamus and posterior pituitary showed no abnormalities.
Habener et al 45 introduced into transgenic mice a fusion gene construct that included the metallothionein-1 (MT1) promoter driving the rat vasopressin structural gene. The MTl-vasopressin transgene expressed vasopressin mRNA in liver and kidney, as expected with the MT1 promoter. The transgene was also expressed in the brain (including hypothalamus), intestines, and pancreas, with correct processing of vasopressin peptide in brain and pancreas. Low levels of transgene expression were also detected in heart, lungs, and spleen. It is not possible to definitely attribute expression in the brain and pancreas to vasopressinspecific sequences, as the rat vasopressin gene in the fusion construct included only 36 bases upstream to the transcription start site. However, there also may be important enhancer sequences within the structural sequence or in the 3' flanking region of the vasopressin gene. Interestingly, these transgenic mice developed diabetes insipidus despite elevated levels of vasopressin. It was hypothesized that they had developed renal resistance to vasopressin action due to long-term exposure to increased levels of vasopressin. 45 Other mouse lines transgenic for vasopressin constructs have been reported, but not fully characterized, in the literature. Neuronal expression of the transgene was studied in mice carrying a fusion gene containing 1.5 kb of the human vasopressin promoter and the human growth hormone structural gene. Growth hormone mRNA was expressed at high levels in the cerebral cortex as well as throughout the hypothalamus. 46 When 2.8 kb of the promoter sequence together with the first exon and first intron of the mouse vasopressin was used to drive the lacZ reporter gene, )3-galactosidase was expressed in testes, heart, and brain. 47 A 13.4-kb bovine vasopressin construct with 7 kb of upstream sequence was expressed in the ovaries of transgenic mice. Some animals carrying this construct also had low-level expression in hypothalamus. 48 Young et al 49 developed transgenic mice using a chimeric gene containing the rat vasopressin coding sequence with 1.4 kb of upstream sequence and 0.3 kb of downstream sequence fused to the rat oxytocin gene with 0.4 kb of upstream sequence. Rat oxytocin mRNA was detected in the oxytocin-expressing magnocellular neurons of the hypothalamus, but no transgenic rat vasopressin mRNA was detected in the brain. Examination of other tissues from these transgenic mice was not reported. These results were interpreted to suggest that there was interdependent regulation of the vasopressin and oxytocin genes that lie within 11 kb or less of each other in the genome. Appropriate cell-specific expression is not seen with transgenes containing up to 1.3 kb of the oxytocin promoter. Therefore, the cellspecific expression of oxytocin observed with the vasopressin-oxytocin chimeric transgene was attributed to sequences in the 3.6-kb vasopressin construct.
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Development of Transgenic Mice With an 8.2-kb
Rat Vasopressin Gene The findings of these previously reported studies demonstrate that the 5' promoter sequence is not sufficient to direct tissue-specific expression of the vasopressin gene. Therefore, important cis-acting elements may be present in the 3' flanking region or vasopressin structural sequence. It is not known which, if any, regions of the vasopressin gene are important in the regulation of mRNA poly(A) tail length. Regulation of vasopressin mRNA poly(A) tail length is seen in the rat but not the mouse hypothalamus. 34 - 50 Transgenic placement of the rat vasopressin gene into cells of the mouse hypothalamus could demonstrate the relative contribution of cis-acting sequences in the vasopressin gene and cell-specific /rans-activating factors in the regulation of poly(A) tail length. An 8.2-kb genomic clone of the rat vasopressin gene was used to develop mice transgenic for a normal vasopressin gene. 50 The 8.2-kb construct included 3 kb each of 5' and 3' flanking sequences in addition to the unaltered 2.2-kb structural vasopressin gene. After pronuclear microinjection of the vasopressin genomic construct, 3841 two founders were identified, and heterozygous offspring of one of the founders were studied to determine if there was tissue-specific expression and appropriate osmotic regulation of the transgene. 50 Tissue-specific expression of the rat vasopressin transgene was demonstrated by comparing expression of the transgene with the distribution seen in the nontransgenic mouse and normal rat. Because of the high degree of similarity between the rat and mouse vasopressin genes, 28 -29 a technique was required that would specifically and sensitively identify the expression 50 After extraction of total RNA, cDNA is synthesized with reverse transcriptase and random hexamer primers. 51 The cDNA is amplified by pofymerase chain reaction using two primers (PI and P2) of transgenic rat and endogenous mouse vasopressin mRNA. Reverse transcription of total RNA with polymerase chain reaction amplification and restriction digestion (Fig 3) was used to assess vasopressin mRNA expression in tissues from transgenic and nontransgenic mice and normal rats.
In nontransgenic mice and normal rats, expression of the vasopressin gene was detected in hypothalamus and temporal lobe, with lower levels of expression in posterior pituitary, parietal cerebral cortex, and cerebellum. In the transgenic mice, there was expression of transgenic rat vasopressin mRNA in the same organs and at qualitatively similar levels as vasopressin mRNA detected in normal rats and mice (Table) . Therefore, neuronal expression of the rat vasopressin transgene closely resembles the distribution seen in nontransgenic mouse and normal rat. There was also very low-level expression of the rat vasopressin transgene in lung and pancreas. This may represent lack of specificity of the transgene. However, vasopressin peptide has been identified in the pancreas of many species, 18 ' 19 and the lung is a well-known site of pathological vasopressin expression.
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Demonstration of Osmotic Regulation of the
Vasopressin Transgene The response of hypothalamic vasopressin mRNA levels to the osmotic stimulus of water deprivation was studied in transgenic mice, nontransgenic mice, and normal rats. 50 Quantitative studies of hypothalamic vasopressin mRNA were performed with Northern blot analysis using rat-and mouse-specific cRNA probes. With dehydration, transgenic rat vasopressin mRNA increased approximately sevenfold, and endogenous mouse vasopressin mRNA increased approximately twofold. This compares with the 1.3-fold response seen in normal rats and the approximately fivefold increase observed in nontransgenic mice with water deprivation. The length of transgenic rat vasopressin mRNA did not increase with dehydration, as seen in the normal rat hypothalamus. Instead, after water deprivation of the transgenic mice, shorter transgenic rat and endogenous mouse vasopressin mRNAs appeared, with preservation of basal length mRNA. Regulation of vasopressin mRNA poly(A) tail length was similar for both the endogenous mouse and transgenic rat mRNAs. Therefore, in mice transgenic for the 8.2-kb rat vasopressin gene construct, there was osmotic regulation of both the quantity and the pofy(A) tail length of vasopressin mRNA. These findings suggest that the 8.2-kb sequence, with 3 kb each of 5' and 3' flanking sequences in addition to the 2.2-kb vasopressin structural gene, contains the cu-acting sequences necessary for tissue-specific expression and osmotic regulation of the vasopressin gene. However, regulation of poly(A) tail length in response to an osmotic stimulus is dependent, in part, on host cell-specific factors.
Physiological Studies of Mice Transgenic for the
Rat Vasopressin Gene The vasopressin peptide sequence is highly conserved among species, and nearly all mammals, including rat and mouse, have the same nine-amino acid arginine vasopressin sequence. 54 Therefore, radioimmunoassay cannot differentiate vasopressin peptide encoded by the transgenic rat gene or by the endogenous mouse gene. Plasma levels of vasopressin measured by radioimmunoassay were similar in both nontransgenic and heterozygous transgenic mice. 53 Posterior pituitary content of vasopressin was also unchanged by expression of the transgene. However, in these transgenic mice, vasopressin peptide levels in the hypothalamus and temporal lobe were greater compared with nontransgenic animals. Detection of possible low levels of tissue vasopressin in other tissues would have been obscured by plasma vasopressin present in blood trapped in the organs. Expression of the vasopressin transgene appears to have no effect on water metabolism, as there is no significant difference in 24-hour urine volume or urine osmolality between transgenic and nontransgenic mice. 55 With additional breeding, mice homozygous for the rat vasopressin transgene have been obtained. These mice have even greater levels of vasopressin peptide in hypothalamus and cerebral cortex, but pituitary vasopressin peptide levels are no different than those seen with the heterozygous transgenic and nontransgenic mice. Plasma vasopressin levels were increased threefold to fourfold compared with heterozygous and nontransgenic animals. However, despite these increased levels of immunoreactive vasopressin, there was no effect on 24-hour urine volume or urine osmolality. 55 The increase in vasopressin levels in the homozygous compared with heterozygous transgenic animals suggests that there may be a dose effect of the transgene. In normal rats, hyposmolar conditions can fully suppress synthesis of vasopressin peptide. 56 However, the homozygous transgenic mice maintain normal urine volume and osmolality, despite elevated plasma vasopressin levels. This suggests that the transgenic mice may be partially resistant to the effects of vasopressin. This effect might be due to renal resistance to vasopressin similar to that reported in mice transgenic with an overexpressing MTl-vasopressin construct. 45 Further study of the physiology of the homozygous mice will be necessary to determine the response of these homozygous transgenic mice to various osmotic stimuli.
Early observations suggested that, compared with nontransgenic and heterozygous transgenic mice, mice homozygous for the rat vasopressin transgene had lower systolic blood pressures. 57 However, subsequent evaluation of a larger cohort of animals has shown no statistical difference in blood pressure among nontransgenic, heterozygous transgenic, and homozygous transgenic mice (unpublished observations).
Summary
The physiological regulation of vasopressin has been well studied in whole animal models. More recent studies have demonstrated additional details regarding the regulation of vasopressin gene expression with in vitro models, such as cultured cells. Transgenic animals provide a system that bridges the gap between these two methodologies. Previous mouse lines transgenic for vasopressin constructs have suggested that the 5' promoter sequence is not sufficient to direct tissue-specific expression of the vasopressin gene. The transgenic mice heterozygous for an 8.2-kb rat vasopressin genomic construct that includes 3 kb each of 5' and 3' flanking sequences in addition to the 2.2-kb vasopressin structural sequence have tissue-specific expression of the transgene, with a distribution similar to that seen in the normal rat and mouse. With osmotic stimulation, there is appropriate regulation of transgenic vasopressin mRNA quantity which resembles that seen in the nontransgenic mouse. Regulation of vasopressin mRNA poly(A) tail length is host cell specific, suggesting that cell-specific /ra/w-activating factors as well as ds-acting sequences in the vasopressin gene are important in this function. Despite increased hypothalamic levels of arginine vasopressin peptide, both heterozygous and homozygous transgenic mice have normal levels of arginine vasopressin in the posterior pituitary and normal basal water metabolism. Mice transgenic for altered constructs of the 8.2-kb rat vasopressin gene should be useful for further studies of the physiological importance of various ciy-acting elements of the gene and may provide information on the role of the vasopressinassociated neurophysin and glycopeptide. 
